Indian PM’s Balancing Act: Patents Or Access To Meds?
This article was originally published in PharmAsia News
India’s intellectual property laws have bitterly divided global drug firms and their Indian counterparts. With the forthcoming visit of Indian Prime Minister Narendra Modi to the U.S., that debate is back. But neither side looks likely to yield any ground, raising more questions than solutions.